^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

IL6 elevation

i
Other names: IL6, BSF2, HGF, HSF, IFNB2, IL-6, Interleukin 6
Entrez ID:
Related biomarkers:
10d
Construction and validation of a risk prediction model for postoperative lung infection in elderly patients with lung cancer. (PubMed, Medicine (Baltimore))
Age > 70 years, smoking history, diabetes history, prolonged use of perioperative antibiotics, and elevated CRP, IL-6, and IGF-1 levels on the 1st day after surgery have an impact on postoperative lung infection in elderly patients with LC. Early postoperative monitoring of changes in CRP, IL-6, and IGF-1 levels can provide an important reference for predicting the occurrence of postoperative lung infections.
Retrospective data • Journal
|
IL6 (Interleukin 6) • IGF1 (Insulin-like growth factor 1) • CRP (C-reactive protein)
|
IL6 elevation • IGF1 elevation
24d
An autopsy case of gas gangrene, massive intravascular hemolysis, and cytokine storm due to Clostridium perfringens type A infection. (PubMed, IDCases)
Elevated interleukin 6 and tumor necrosis factor-α expression levels were observed in the serum, and such proinflammatory responses were partially mediated by Toll-like receptor 2. This study elucidated the association between the toxin profiles of clinically isolated C. perfringens and the host cytokine responses in the patient.
Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • TLR2 (Toll Like Receptor 2)
|
IL6 elevation • IL6 expression
2ms
Knockdown of IGF2BP3 Down-Regulates PDCD4 Levels to Attenuate Hypoxic-Ischemic Brain Damage. (PubMed, Front Biosci (Landmark Ed))
PDCD4 and m6A reader protein IGF2BP3 were up-regulated in an HIBD neonatal rat model. Knockdown of IGF2BP3 in OGD/R-stimulated PC12 cells or PCNs alleviated cell damage through reducing PDCD4.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3)
|
IL6 elevation
2ms
Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study. (PubMed, Br J Cancer)
Higher pre-diagnosis IL-6 levels suggest poorer long-term survival among BC survivors. In postmenopausal survivors, elevated IL-6, IL-10, and TNFα and inflammatory scores seem to predict all-cause mortality.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
|
HER-2 negative • IL6 elevation
2ms
Soluble biomarkers for immune checkpoint inhibitor-related encephalitis: A mini-review. (PubMed, Rev Neurol (Paris))
Likewise, the value of other biomarkers, including T cells markers and HLA haplotypes, still needs to be evaluated in large cohorts. Overall, neural antibodies are important diagnostic and prognostic biomarkers in ICI-encephalitis, and other soluble biomarkers, especially NfL, deserve further investigation since they have a promising application in clinical practice.
Review • Journal • Checkpoint inhibition • IO biomarker
|
IL6 (Interleukin 6) • S100B (S100 Calcium Binding Protein B)
|
IL6 elevation
2ms
Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model. (PubMed, Target Oncol)
These modeling results suggest that IL-6 release due to talquetamab-induced cytokine release syndrome has limited impact on potential drug-drug interactions, with the highest likelihood of impact occurring from initiation of talquetamab step-up dosing up to 7 (QW) or 9 (Q2W) days after first treatment dose in cycle 1 and during and after cytokine release syndrome. Multiple myeloma can be treated with immunotherapies such as the bispecific antibody, talquetamab, which binds the novel antigen G protein-coupled receptor family C group 5 member D on multiple myeloma cells and CD3 on T cells and induces T-cell-mediated lysis of multiple myeloma cells. Following talquetamab treatment, many patients experience cytokine release syndrome, an inflammatory immune response where levels of proinflammatory cytokines, including interleukin (IL)-6, are increased. Interleukin-6 can suppress the activity of important enzymes in the body (cytochrome [CYP] P450s) that are involved in drug clearance. This study used a physiologically based pharmacokinetic computer model to investigate the potential impact of increased IL-6 levels on CYP450 enzymes to determine subsequent impact on drugs that are metabolized by CYP450 enzymes. The results showed no predicted interaction between median levels of IL-6 observed in patients and CYP substrates (such as caffeine and omeprazole) with talquetamab. In a simulation that assessed higher (maximum) IL-6 levels observed in patients, the predicted impact of IL-6 was minimal to weak for most of the CYP substrates assessed. The effect on CYP450 enzymatic activity was highest from initiation of talquetamab step-up dosing up to 7-9 days after the first treatment dose of talquetamab. These results suggest that, in this treatment time period, elevated IL-6 levels due to talquetamab-induced cytokine release syndrome have limited impact on drugs that are CYP substrates that may be used in conjunction with talquetamab, but that the concentration and toxicity of these drugs should be monitored and the dose of CYP substrate adjusted as required.
PK/PD data • Journal
|
IL6 (Interleukin 6) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5)
|
IL6 elevation
|
Talvey (talquetamab-tgvs) • omeprazole
2ms
Unravelling the role of dipeptidyl peptidases-8/9 (DPP-8/9) in inflammatory osteoporosis: a comprehensive study investigating chrysin as a potential anti-osteoporotic agent. (PubMed, J Pharm Pharmacol)
This study highlights the role of DPP-8/9 in inflammation-induced osteoporosis. Following inhibition of DPP-8/9, we observed improved bone markers with preservation of trabecular bone mineral density in rats. Additionally, chrysin demonstrated potential as an anti-DPP-8/9 agent, suggesting its viability for future therapeutic interventions in DPP-8/9-related inflammatory diseases.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
IL6 elevation
2ms
Associations of Placental Inflammation and Oxidative Stress Biomarkers with Glucolipid Metabolism in Children: A Birth Cohort Study in China. (PubMed, J Am Heart Assoc)
This exploratory study underscores significant correlations between maternal intrauterine placental inflammation, oxidative stress markers, and offspring fasting blood glucose and insulin levels. These findings highlight the potential role of intrauterine holistic immunity in shaping offspring glucose metabolism health.
Journal
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • HMOX1 (Heme Oxygenase 1) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • CRP (C-reactive protein)
|
IL6 elevation
6ms
The association of inflammatory biomarkers and long-term clinical outcomes in older adults with non-ST elevation acute coronary syndrome. (PubMed, Int J Cardiol)
Among older NSTEACS patients, elevated IL-6 and hsCRP were associated with increased risk of all-cause mortality and MACCE, respectively. Low MPO levels were associated with higher MACCE. Further studies are required to determine how these biomarkers should influence treatment strategy in this understudied subset.
Clinical data • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein) • MPO (Myeloperoxidase)
|
IL6 elevation
6ms
Plasma profiles of inflammatory cytokines in children with moderate to severe traumatic brain injury: a prospective cohort study. (PubMed, Eur J Pediatr)
After m-sTBI, the plasma profiles of inflammatory cytokines are markedly altered in children. The trends of IL-6 and IL-8 expression vary among m-sTBI children with different outcomes. Elevated plasma IL-6 and IL-8 levels are related to in-hospital mortality and unfavorable 6-month outcomes.
Journal
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL17A (Interleukin 17A) • IFNA1 (Interferon Alpha 1) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
|
IL6 elevation • CXCL8 elevation • CXCL8 expression • IL10 elevation • IL6 expression
6ms
Longitudinal Study on Salivary IL-6 Trajectories in Postoperative OSCC Patients After Chemotherapy and Radiotherapy. (PubMed, J Stomatol Oral Maxillofac Surg)
Salivary IL-6 emerges as a promising biomarker in OSCC management, necessitating further research to harness its diagnostic and therapeutic potential. By understanding IL-6 dynamics, personalized treatment approaches can be developed to improve patient outcomes. Longitudinal studies with larger cohorts and multi-omics approaches are warranted to validate findings and identify novel therapeutic targets.
Observational data • Journal
|
IL6 (Interleukin 6)
|
IL6 elevation • IL6 expression
7ms
The Role of Pretreatment Serum Interleukin 6 in Predicting Short-Term Mortality in Patients with Advanced Pancreatic Cancer. (PubMed, Biomedicines)
With a median follow-up of 9.28 months, patients with lower IL-6 levels experienced markedly better median overall survival and progression-free survival than those with higher levels, underscoring IL-6's role in predicting disease prognosis. Multivariate analysis further confirmed IL-6 levels, alongside older age, and elevated neutrophil-to-lymphocyte ratio, as predictors of worse outcomes, suggesting that IL-6 could be a critical biomarker for tailoring treatment strategies in advanced PDAC, warranting further investigation into its role in systemic inflammation and the tumor microenvironment.
Journal • Metastases
|
IL6 (Interleukin 6)
|
IL6 elevation • IL6-L • Albumin-L
7ms
Elevated IL-6 levels in a patient with pheochromocytoma. (PubMed, BMJ Case Rep)
She was initiated on naproxen (NPX) at a dose of 250 mg two times per day. The patient responded to NPX, and after stabilisation, she underwent an adrenalectomy. There was a complete resolution of fever with normalisation of IL-6 levels postoperatively.
Journal
|
IL6 (Interleukin 6)
|
IL6 elevation
7ms
Derangements of immunological proteins in HIV-associated diffuse large B-cell lymphoma: the frequency and prognostic impact. (PubMed, Front Cell Infect Microbiol)
Elevation of TGFβ, IL-10 and ferritin were associated with survival independently from the IPI. In view of the poor survival rates in this cohort, investigation of the directed targeting of these cytokines would be of interest in our setting.
Retrospective data • Journal
|
IL6 (Interleukin 6) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • CRP (C-reactive protein)
|
IL6 elevation
7ms
Life-Threatening MOG Antibody-Associated Hemorrhagic ADEM With Elevated CSF IL-6. (PubMed, Neurol Neuroimmunol Neuroinflamm)
He improved after plasma exchange, then began monthly treatment alone with anti-IL-6 receptor antibody, tocilizumab, and has remained stable. This case highlights how adult-onset MOGAD, like childhood ADEM, can rapidly become life-threatening. The markedly elevated CSF IL-6 observed here supports consideration for evaluating CSF cytokines more broadly in patients with acute MOGAD.
Journal
|
IL6 (Interleukin 6)
|
IL6 elevation
|
Actemra IV (tocilizumab)
7ms
Effect and mechanism of Maxing Shigan Decoction on reducing inflammatory response in rats with cough variant asthma via TLR4/MyD88/NF-κB and p38 MAPK signaling pathways (PubMed, Zhongguo Zhong Yao Za Zhi)
The number of white blood cells, the levels of IL-10 and TNF-α in the serum, the protein levels of TLR4, MyD88, p-p65/NF-κB p65, and p-p38 MAPK/p38 MAPK, and the mRNA levels of TLR4 and MyD88 in the lung tissue showed no significant differences between the Montelukast sodium group and high-dose Maxing Shigan Decoction group. Maxing Shigan Decoction can inhibit airway inflammation in CVA rats by inhibiting the activation of TLR4/MyD88/NF-κB and p38 MAPK signaling pathways.
Preclinical • Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • TLR4 (Toll Like Receptor 4)
|
IL6 elevation
7ms
Co-Culture of P. gingivalis and F. nucleatum Synergistically Elevates IL-6 Expression via TLR4 Signaling in Oral Keratinocytes. (PubMed, Int J Mol Sci)
This effect depends on TLR4 because TLR4 knockdown notably impacts IL-6 expression and cell migration. Our study unveils, for the first time, crucial insights into the outcomes of their co-culture on virulence, unraveling the role of bacterial interactions in polymicrobial diseases and potential links to oral cancer.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • TLR4 (Toll Like Receptor 4) • IL1B (Interleukin 1, beta)
|
IL6 elevation • CXCL8 expression • IL6 expression
7ms
Selective microRNA expression of exosomes from retinal pigment epithelial cells by oxidative stress. (PubMed, Vision Res)
Finally, Gene Ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were used to find the possible target genes of those selective exosomal miRs. Our results proved that the RPE-derived exosomes after OS selectively express certain miRs, providing novel insights into the pathogenesis of age-related macular degeneration (AMD) in future.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MIR7 (MicroRNA 7) • IL1B (Interleukin 1, beta) • MIR125A (MicroRNA 125a) • MIR128 (MicroRNA 128)
|
IL6 elevation • IL6 expression
8ms
High plasma interleukin-6 level, but not IL-6 gene variants, as a predictive marker for the development of hepatocellular carcinoma in a Moroccan population. (PubMed, Int J Immunogenet)
Contrastingly, the genotype and allele distributions of the rs1800795 and rs1800797 polymorphisms in the IL-6 gene displayed no association with HCC development (all p > .005). In Moroccan HCC patients, chronic liver inflammation is characterized by elevated levels of IL-6, potentially playing a role in the progression of liver disease and tumourigenesis.
Journal
|
IL6 (Interleukin 6)
|
IL6 elevation
8ms
The Role of Inflammatory Biomarkers in Mediating the Effect of Inflammatory Bowel Disease on nonmalignant Digestive System Diseases: A Multivariable Mendelian Randomized Study. (PubMed, Can J Gastroenterol Hepatol)
In addition, the presence of AP and IBS may indicate the presence of UC. Preventing CeD is an essential consideration in the therapeutic management of patients with CD.
Journal
|
IL6 (Interleukin 6)
|
IL6 elevation
8ms
How is inflammation biology truly associated with depression in patients with stable coronary heart disease?: Insights from the heart and Soul study. (PubMed, Brain Behav Immun Health)
Inflammatory markers were not consistent predictors of factor loadings. This study represents the initial step to discussing how inflammation biology is truly related to depression among patients with established CHD.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CCL2 (Chemokine (C-C motif) ligand 2) • CRP (C-reactive protein)
|
IL6 elevation
8ms
AT1001 for the Treatment of COVID-19 Related MIS-C (clinicaltrials.gov)
P2, N=20, Recruiting, Massachusetts General Hospital | Phase classification: P2a --> P2 | Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Sep 2022 --> Jun 2025
Phase classification • Trial completion date • Trial primary completion date
|
IL6 (Interleukin 6) • CRP (C-reactive protein)
|
IL6 elevation • Albumin-L
9ms
Cryptogenic non-cirrhotic HCC: Clinical, prognostic and immunologic aspects of an emerging HCC etiology. (PubMed, Sci Rep)
This cryptogenic variant exhibits distinct traits, such as advanced tumors and increased symptoms, and most resemble burned-out NAFLD. Understanding this HCC variant is crucial for improving screening and management strategies.
Journal
|
IL6 (Interleukin 6) • PNPLA3 (Patatin Like Phospholipase Domain Containing 3)
|
IL6 elevation
9ms
Anti-inflammatory effects of α-humulene on the release of pro-inflammatory cytokines in lipopolysaccharide-induced THP-1 cells. (PubMed, Cell Biochem Biophys)
TNF-α as well as IL-1β cytokine concentrations were not reduced by the addition of 0.5 and 100 µM α-humulene. This study suggests that α-humulene has potential as a promising natural alternative to established pharmaceuticals for the treatment of elevated IL-6 levels and chronic inflammation in humans.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
|
IL6 elevation
9ms
The anti-neoplastic effects of metformin modulate the acquired phenotype of fibroblast cells in the breast cancer-normal fibroblast co-culture system. (PubMed, Oncol Res)
Metformin, however, may change this state and affect fibroblasts' acquired phenotypes. Moreover, mitochondrial inhibition by metformin after 8 days of treatment, significantly hinders tumor growth in mouse model of breast cancer.
Journal
|
IL6 (Interleukin 6) • CAV1 (Caveolin 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
IL6 elevation
|
metformin
9ms
Case report: Kikuchi-Fujimoto disease: unveiling a case of recurrent fever and enlarged cervical lymph nodes in a young female patient with a literature review of the immune mechanism. (PubMed, Front Immunol)
Eventually, the patient achieved disease relief through steroid treatment. Based on these findings, we conducted a comprehensive review of the involvement of viral infection-induced inflammatory response processes and autoimmunity in the pathogenesis of Kikuchi-Fujimoto disease.
Clinical • Clinical protocol • Observational data • Retrospective data • Review • Clinical Trial,Phase III • Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD4 (CD4 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
|
IL6 elevation
9ms
Nomograms confirm serum IL-6 and CRP as predictors of immune checkpoint inhibitor efficacy in unresectable hepatocellular carcinoma. (PubMed, Front Immunol)
Nomograms are well-structured and validated prognostic maps constructed from three variables, as MVI, IL6 and CRP. Low levels of IL-6 and CRP have a positive correlation with efficacy for uHCC patients receiving ICIs.
Retrospective data • Journal • Checkpoint inhibition
|
IL6 (Interleukin 6) • CRP (C-reactive protein)
|
IL6 elevation
10ms
Elevated 18F-FDG uptake in subcutaneous adipose tissue correlates negatively with nutritional status and prognostic survival in cachexia patients with gastric cancer. (PubMed, Clin Nutr)
Browning of subcutaneous adipose tissue was markedly elevated in cachectic gastric cancer patients compared to non-cachectic counterparts. Increased 18F-FDG uptake in subcutaneous adipose tissue in cachectic gastric cancer patients was inversely correlated with nutritional status and survival prognosis.
Journal
|
IL6 (Interleukin 6)
|
IL6 elevation
11ms
REVIEW OF THE NATURE OF ANTI/INFLAMMATORY AND PRO-INFLAMMATORY CYTOKINE REGULATION IN DIFFERENT PERIODS OF PLASMA CELL MYELOMA NATURAL HISTORY IN THE CHORNOBYL NPP ACCIDENT SURVIVORS. (PubMed, Probl Radiac Med Radiobiol)
Determining the serum level of pro-inflammatory and anti-inflammatory cytokines (IL-6, TNF-α and IL-10 respectively) provides advancement in assessment of the PCM course and predict the effectiveness of administration of therapy protocols.
Review • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
|
IL6 elevation
11ms
Effects of Toll-like receptor 1 and 2 agonist Pam3CSK4 on uveal melanocytes and relevant experimental mouse model. (PubMed, Exp Eye Res)
UM can produce IL-6, MCP-1, CXCL-1, and CXCL-8, and are one of the target cells of TNF-α and IFN-γ. TLR-2 inhibitors might have a beneficial effect in the treatment of certain types of uveitis and other ocular inflammatory-related diseases and warrant further investigation.
Preclinical • Review • Journal • IO biomarker
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • MAPK8 (Mitogen-activated protein kinase 8) • TLR2 (Toll Like Receptor 2)
|
IL6 elevation • IL6 expression
11ms
Elevated serum IL-6 and total IgEAb are associated with poor survival in natural killer/T-cell lymphoma. (PubMed, Ann Hematol)
We found that IL-6 and total IgEAb were significant prognostic factors in NKTCL patients. Also, extranasopharyngeal site was correlated with advanced disease.
Journal
|
IL6 (Interleukin 6)
|
IL6 elevation
11ms
Associations Between Serum TNF-α, IL-6, hs-CRP and GLMD in Obese Children and Adolescents: A Cross-Sectional Study. (PubMed, Diabetes Metab Syndr Obes)
There may be correlations between serum TNF-α, IL-6, hs-CRP levels and GLMD in obese children and adolescents. Attention should be paid to monitoring serum inflammatory factors and preventing their elevation in obese children and adolescents, thus reducing the occurrence of GLMD.
Observational data • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein)
|
IL6 elevation
12ms
Interleukin-6 Facilitates Acute Myeloid Leukemia Chemoresistance via Mitofusin 1-Mediated Mitochondrial Fusion. (PubMed, Mol Cancer Res)
In an MLL::AF9 fusion gene-induced AML mouse model, IL6 reduced chemosensitivity to cytarabine (Ara-C), a commonly used antileukemia drug, accompanied by increased MFN1 expression, mitochondrial fusion, and OXPHOS status...Implications: IL-6 treatment induces MFN1-mediated mitochondrial fusion, promotes OXPHOS, and confers chemoresistance in AML cells. Targeting IL-6 regulation in mitochondria is a promising therapeutic strategy to enhance the chemosensitivity of AML.
Journal
|
IL6 (Interleukin 6) • MFN1 (Mitofusin 1)
|
IL6 elevation
|
cytarabine
12ms
Evaluation of the Potential Impact on Pharmacokinetics of Various Cytochrome P450 Substrates of increasing IL-6 Levels following administration of the T-cell bispecific engager Glofitamab. (PubMed, CPT Pharmacometrics Syst Pharmacol)
It is recommended that there are no restrictions on concomitant treatment with any other drugs. Consideration may be given for potential DDI during the first cycle in patients who are receiving concomitant CYP substrates with a narrow therapeutic index via monitoring for toxicity or for drug concentrations.
PK/PD data • Journal
|
CD20 (Membrane Spanning 4-Domains A1) • IL6 (Interleukin 6) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
IL6 elevation • CD20 expression
|
Columvi (glofitamab-gxbm)
12ms
Inhibition of soluble epoxide hydrolase relieves adipose inflammation via modulating M1/M2 macrophage polarization to alleviate airway inflammation and hyperresponsiveness in obese asthma. (PubMed, Biochem Pharmacol)
These processes were found to act through ERK1/2 signaling pathway. Herein, we proved that inhibition of sEH expression helped to mitigate multiple parameters of obese asthma by regulating the balance of M1/M2 macrophage polarization in adipose tissue.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
|
IL6 elevation
12ms
Scutellarin Alleviates Diabetic Retinopathy via the Suppression of Nucleotide-Binding Oligomerization Domain (NOD)-Like Receptor Pyrin Domain Containing Protein 3 Inflammasome Activation. (PubMed, Curr Eye Res)
Additionally, scutellarin effectively inhibited the expression of NOD-like receptor pyrin domain containing protein 3 inflammasome-related markers in the retinal tissues of streptozotocin-administered rats. Collectively, our results indicate that scutellarin significantly reduces streptozotocin-induced retinal inflammation, an effect that may be partially attributed to the suppression of NLRP3 inflammasome activation.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • NLRC5 (NLR Family CARD Domain Containing 5) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • CAT (Catalase)
|
IL6 elevation
12ms
Manifestations of Liver Impairment and the Effects of MH-76, a Non-Quinazoline α1-Adrenoceptor Antagonist, and Prazosin on Liver Tissue in Fructose-Induced Metabolic Syndrome. (PubMed, Metabolites)
Later studies have shown that quinazoline-based α1-adrenolytics (prazosin, doxazosin) induce apoptosis; however, this effect was independent of α1-adrenoceptor blockade and was associated with the presence of quinazoline moiety. Moreover, the MH-76 hepatotoxicity in hepatoma HepG2 cells was less than that of prazosin. The use of α1-adrenolytics with anti-inflammatory properties may be an interesting option for treatment of hypertension with metabolic complications.
Journal
|
IL6 (Interleukin 6) • LEP (Leptin)
|
IL6 elevation
12ms
Cytokine Levels in Neonates: Unveiling the Impact of Perinatal Inflammation on Prematurity. (PubMed, Am J Perinatol)
· There is a direct association between cytokine levels and prematurity. · Knowledge of the variation of cytokines in newborns enhances personalized interventions. · Cytokine levels are early associated with gestational age.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1)
|
IL6 elevation • CXCL8 elevation
12ms
NANOG Dominates Interleukin-6-Induced Sphere Formation in Prostate Cancer. (PubMed, Urol Res Pract)
Inducing IL-6 in prostate tumor spheres stimulates stemness biomarker NANOG genes. NANOG may be suggested as a therapeutic target for metastatic prostate cancer.
Journal
|
IL6 (Interleukin 6) • NANOG (Nanog Homeobox)
|
IL6 elevation • IL6 expression
1year
Inb-100: A Pilot Study of Donor Derived, Ex-Vivo Expanded/Activated Gamma-Delta T Cell (EAGD) Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-Transplant Cyclophosphamide (PTCy) (ASH 2023)
Post-BMT infusion of donor-derived, EAGD cells has demonstrated manageable safety with no infusional toxicity or ≥G3 acute GvHD or extensive chronic GvHD. Durable relapse free survival at a maximum of >3 years in subjects with poor risk cytogenetics and adverse clinical risk factors combined with ongoing homeostatic reconstitution of increasing gd T cell effectors post-BMT suggests this therapy may be an effective measure in mitigating relapse after HaploBMT. NCT03533816
Preclinical • Post-transplantation
|
IL6 (Interleukin 6) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD27 (CD27 Molecule) • IL15 (Interleukin 15)
|
IL6 elevation
|
cyclophosphamide • INB-100